{"id":"apg-115","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"APG-115 works by selectively inhibiting the BCL-2 family proteins, which are involved in regulating cell death and survival. This inhibition can lead to the induction of apoptosis in cancer cells. By targeting these proteins, APG-115 aims to selectively kill cancer cells while sparing normal cells.","oneSentence":"APG-115 is a small molecule inhibitor of BCL-2 family proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:41.533Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06654050","phase":"PHASE2","title":"Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-16","conditions":"Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma","enrollment":""},{"nctId":"NCT03781986","phase":"PHASE1, PHASE2","title":"APG-115 in Salivary Gland Cancer Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-10-28","conditions":"Malignant Salivary Gland Cancer, Salivary Gland Cancer","enrollment":41},{"nctId":"NCT04496349","phase":"PHASE2","title":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-07-12","conditions":"T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma","enrollment":78},{"nctId":"NCT03611868","phase":"PHASE1, PHASE2","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2018-08-29","conditions":"Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma","enrollment":230},{"nctId":"NCT06735820","phase":"PHASE1, PHASE2","title":"Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST","status":"NOT_YET_RECRUITING","sponsor":"AeRang Kim","startDate":"2025-10-01","conditions":"Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1), Atypical Neurofibroma","enrollment":45},{"nctId":"NCT04785196","phase":"PHASE1, PHASE2","title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-05-26","conditions":"Liposarcoma, Advanced Solid Tumor","enrollment":95},{"nctId":"NCT05701306","phase":"PHASE1","title":"APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-02-28","conditions":"Neuroblastoma, Solid Tumor","enrollment":100},{"nctId":"NCT04275518","phase":"PHASE1","title":"A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-07-06","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":102},{"nctId":"NCT04358393","phase":"PHASE1, PHASE2","title":"A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-12-04","conditions":"AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":69},{"nctId":"NCT02935907","phase":"PHASE1","title":"APG-115 in Patients With Advanced Solid Tumors or Lymphomas","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2016-10","conditions":"Patients With Advanced Solid Tumor or Lymphoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["alrizomadlin"],"phase":"phase_2","status":"active","brandName":"APG-115","genericName":"APG-115","companyName":"Ascentage Pharma Group Inc.","companyId":"ascentage-pharma-group-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APG-115 is a small molecule inhibitor of BCL-2 family proteins. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}